RDD Blog » CRO

R&D Directions Insider

‘Lower costs and better outcomes are mission critical’ for sponsors

Wednesday, July 27th, 2011

We reported last week that Wendel Barr, the former chief operating officer at contract research giant Covance and 11-year executive with the company, was named CEO of Synteract, a smaller privately held CRO based in San Diego. We caught up with Mr. Barr after his move across country (Covance headquarters are ...

Posted in CRO, Uncategorized | No Comments »

Covance exec takes head reins at smaller CRO

Monday, July 18th, 2011

Today, I was alerted to an interesting hire in the CRO arena, where executives jumping from one company to another is fairly common. This one, however â€“ the appointment this morning of Wendel Barr as the new CEO of San Diego-based Synteract Inc. â€“ is worth noting because of the ...

Posted in CRO, Uncategorized | 1 Comment »

CROs juggle uncertainty, optimism

Tuesday, August 10th, 2010

The latest earnings season for the top publicly traded contract research organizations is over (Parexel released fiscal year 2010 results yesterday), leaving eyes now focused ahead at just what path clinical outsourcing will take the rest of the year and beyond. Many CROs are unsure whether continued market conditions will ...

Posted in CRO, clinical trials | 1 Comment »

Charles River’s preclinical site suspension to cost 300 jobs

Monday, January 11th, 2010

Charles River Laboratories International Inc. has provided additional details regarding todayâ€™s announcement that the company is suspending operations at its Shrewsbury, Mass., preclinical facility in the middle of the year. According to the worldâ€™s third-ranked publicly traded CRO, 300 people will be laid off as a result of the move. ...

Posted in CRO | 1 Comment »

PPD puts skin in the game with Celtic alliance

Friday, October 30th, 2009

The typical CRO/sponsor relationship can be prone to delays as a result of the way trials are set up or misunderstandings between the parties. PPD is looking to avoid such delays by bringing products to market more quickly with its recent agreement to invest $100 million in Celtic Therapeutics Holdings ...

Posted in CRO | No Comments »

Growing movement toward independent contracting

Monday, March 9th, 2009

During these tough economic times, when employment opportunities are scarce, more people are looking to other forms of income, such as independent contracting. According to a recent survey conducted by Redtree People Ltd., 60% of clinical research personnel have considered becoming contractors in the past and over 84% said they ...

Posted in CRO, recession | No Comments »

Maple leaf special on patient recruitment

Monday, February 23rd, 2009

The benefits of the Canadian biotechnology market may have you asking why not Canada? Canada has over 500 biotechnology companies, more per capita than any other country and offers the most cost-competitive business environment in the Group of Seven (G7). Canadian biotechnology companies invest about $1.7 billion in research and development ...

Posted in CRO, Uncategorized | No Comments »

©2012 UBM Canon